Bio-Rad Laboratories, Inc.
BIO · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.01 | -0.24 | 0.02 |
| FCF Yield | 1.18% | 1.08% | 1.40% | 0.88% |
| EV / EBITDA | -22.22 | 15.94 | 57.33 | -11.90 |
| Quality | ||||
| ROIC | 0.86% | 0.61% | 0.20% | 0.51% |
| Gross Margin | 52.59% | 52.99% | 52.27% | 51.22% |
| Cash Conversion Ratio | -0.35 | -0.97 | 2.03 | -0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.04% | -2.66% | -2.94% | -2.89% |
| Free Cash Flow Growth | 25.99% | -25.86% | 17.54% | -18.73% |
| Safety | ||||
| Net Debt / EBITDA | -2.59 | 2.17 | 6.35 | -1.05 |
| Interest Coverage | 5.31 | 6.12 | 1.98 | 4.79 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.38 | 0.35 | 0.43 |
| Cash Conversion Cycle | 27.91 | 258.68 | 275.38 | 237.30 |